{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:33:27Z","timestamp":1788870807316,"version":"build-2803163510"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe the clinical presentation and visual outcomes of relentless placoid choroiditis (RPC) in four patients treated with intravenous cyclophosphamide, a treatment not extensively studied in this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>RPC is a rare and recently described ocular disease characterized by a prolonged and progressive clinical course, widespread lesions, and unknown etiology. There is no consensus on its treatment, and the use of cyclophosphamide in RPC has not been extensively studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>Four RPC patients treated with intravenous cyclophosphamide showed significant visual improvement (mean best-corrected visual acuity [BCVA] improved from 20\/125 to 20\/32) with minimal side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case series demonstrates favorable outcomes with intravenous cyclophosphamide in RPC, supporting its potential as a safe, effective, and cost-efficient treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_348_25","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:00:21Z","timestamp":1752850821000},"page":"1576-1580","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of cyclophosphamide therapy in relentless placoid choroiditis: A descriptive case series"],"prefix":"10.4103","volume":"73","author":[{"given":"Miguel","family":"Pedroza-Seres","sequence":"first","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Instituto de Oftalmolog\u00eda FAP Conde de Valenciana, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E","family":"Rodr\u00edguez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Retina and Vitreous, Instituto de Oftalmolog\u00eda FAP Conde de Valenciana, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"R1-20260419","first-page":"931","article-title":"Relentless placoid chorioretinitis: A new entity or an unusual variant of serpiginous chorioretinitis?","volume":"118","author":"Jones","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R2-20260419","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09273940903402637","article-title":"Clinical profile, treatment, and visual outcome of ampiginous choroiditis","volume":"18","author":"Jyotirmay","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R3-20260419","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archophthalmol.2009.368","article-title":"Fundus autofluorescence imaging of the white dot syndromes","volume":"128","author":"Yeh","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R4-20260419","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40942-017-0069-8","article-title":"Multi-modal imaging and anatomic classification of the white dot syndromes","volume":"3","author":"Raven","year":"2017","journal-title":"Int J Retina Vitreous"},{"key":"R5-20260419","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fopht.2021.802962","article-title":"Proposing a neurotropic etiology for acute posterior multifocal placoid pigment epitheliopathy and Relentless placoid chorioretinitis","volume":"1","author":"Steptoe","year":"2022","journal-title":"Front Ophthalmol"},{"key":"R6-20260419","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000442742","article-title":"A case of ampiginous choroiditis","volume":"6","author":"Lambrecht","year":"2015","journal-title":"Case Rep Ophthalmol"},{"key":"R7-20260419","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1442-9071.2008.01773.x","article-title":"Optical coherence tomography in relentless placoid chorioretinitis","volume":"36","author":"Amer","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"R8-20260419","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajoc.2019.03.005","article-title":"Cyclosporine and prednisolone combination therapy as a potential therapeutic strategy for relentless placoid chorioretinitis","volume":"14","author":"Uraki","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R9-20260419","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000500077","article-title":"Relentless placoid chorioretinitis: A case series of successful tapering of systemic immunosuppressants achieved with adalimumab","volume":"10","author":"Asano","year":"2019","journal-title":"Case Rep Ophthalmol"},{"key":"R10-20260419","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulse IV cyclophosphamide in ocular inflammatory disease: Efficacy and short-term safety","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology"},{"key":"R11-20260419","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0002-9343(84)90654-5","article-title":"Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis","volume":"76","author":"Scott","year":"1984","journal-title":"Am J Med"},{"key":"R12-20260419","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/ard.2002.003574","article-title":"EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis","volume":"63","author":"Yee","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R13-20260419","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V85.2.351.351","article-title":"Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura","volume":"85","author":"Reiner","year":"1995","journal-title":"Blood"},{"key":"R14-20260419","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/ard.56.8.481","article-title":"Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide","volume":"56","author":"Martin-Suarez","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"R15-20260419","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/09273948.2016.1237663","article-title":"Short-term intensive immunosuppression: A randomized, three-arm study of intravenous pulse methylprednisolone and cyclophosphamide in macular serpiginous choroiditis","volume":"26","author":"Venkatesh","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R16-20260419","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4103\/0301-4738.158070","article-title":"Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy","volume":"63","author":"Venkatesh","year":"2015","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_348_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:25:35Z","timestamp":1787837135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_348_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_348_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"2025-02-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}